KADCYLA is the first HER2-targeted antibody-drug conjugate

Explore KADCYLA’s components and molecular structure, proposed mechanism of action, and patient eligibility below.

Explore the molecular structure

KADCYLA is a single drug with 3 components.

Proposed mechanism of action

KADCYLA delivers multiple HER2-targeted antitumor activities.

Are your HER2+ MBC patients eligible for KADCYLA?

Get guideline recommendations for KADCYLA and see patient eligibility.